Ipca Laboratories Limited · NSE:IPCALAB
Ipca Laboratories — Investor Presentation (December 2024)
65 slides from Ipca Laboratories's investor presentation, December 2024
Slide 1: Corporate Presentation December 2024
£ipca A dose of life Ipca Laborate Corporate Presentation December 2024
Slide 2: About Us
About Us a Q@©00€ Incorporation Consolidated Income Export to | >16,000 — 70+ —FY203-24 «104 Employees . Manica bs years | 37,830 crs | counties with : ms : ™ USS9500n oneste
Slide 3: Our Values
Our Values a wae Qualiti Safeti Integriti | Digniti _ Responsibilit’ Adhere to Ensure safety Comply with Value Facilitate good standards comes first : ethics & standards; people : business practices
Slide 4: Five Years' Highlights (Standalone)
Five Years’ Highlights XN 6,277.75 %5,925.81 ($757.82) %5,491.22 ($738.69) beeing (5737.38) 4,432.12 ($625.65) 3,570.05 2,983.09 een ($430.96) %2,484.21 1983. ($409.17) 2,288.37 ($333.94) _ eo ‘o——- —O -O —O— bl 2,717.19 2,508.13 2,643.42 ei 22,143.75 (5365.26) (5336.80) ($329.52) . a 652.46 9" 1,14
Slide 5: Five Years' Highlights (Consolidated)
Five Years’ Highlights Consolidated ( 27,829.81 ) 8000 (5945.17) %6,369.94 7000 5,490.83 5,896.36 ($794.06) /AB2. 791.78 6000 ($737.03) ae 24,715.71 5000 ($665.68) 3,391.06 %4090.77 4000 vee en ($422.72) ($493.82) 2,327.88 398.31 : 3000 2 3,739.04 ($328.61) : ($451.35) 2000 2,818.61 2,978.88 —O- i 2
Slide 6: Manufacturing Sites: Formulations
Slide 7: Manufacturing Sites (Formulations)
Manufacturing Sites (Formulations) Kandla Baddi? Dehradun Jorethang (B-lactum) (2 facilities) (2 facilities) (2 facilities) Ratlam , t t New Delhi * + B capital BD Corporate Office ¥ Ghaziabad" B® Formulations BW Biotech Overseas ( y + Mumbai Pithampur Piparia (Biotech) Pisgah Labs Mumbai Athal Tara
Slide 8: Manufacturing Sites (Formulations)
Athal (Dadra & Nagar Haveli) Ratlam (Madhya Pradesh) Kandla (Gujarat) Silvassa (Dadra & Nagar Haveli) Dehradun (Uttarakhand) Indore (SEZ) (Madhya Pradesh) Sikkim Tarapur, Palghar (Maharashtra) Tablets & Capsules Tablets, Liquids, Dry Syrup, Injectables & Ointments Betalactum-Tablets, Capsules & Dry
Slide 9: Manufacturing Sites: Active Pharmaceutical Ingredients
Manufacturing Sites < Active ‘ naceutical Ingredients age : “
Slide 10: Manufacturing Sites (APIs)
Manufacturing Sites (APIs) Onyx Scientific (Sunderland, UK) Baroda Dewas Nandesari New Delhi Ratlam Ranu | GB capital (R&D) : BD Corporate Office apis B® reo Overseas ee ¥ Hingni Mumbai Pithampur’ Mumbai Chh. Sambhajinagar + . (rap) Mahad vy » —_ (2Fadlties) + Pisgah Labs Ankleshwar — Tarapur Kolhap
Slide 11: Manufacturing Sites (APIs)
Manufacturing Sites (APIs) [ Location | Inspections / Approvals by Agencies of ] e@ Ratlam (Madhya Pradesh) Australia, Brazil, Canada, EDQM, EU, India, Japan, Korea, Mexico, Russia, Slovenia, USA, WHO © Indore Madhya Pradesh) nig WHO @ Dewas (Madhya Pradesh) India © Ankleshwar(Gujart) =n Japan Meso
Slide 12: Revenue Break-up
Reven we Break- -up
Slide 13: Revenue Break-up (Standalone 2023-24)
Revenue Break-up (Standalone 2023-24) Total Total Revenue Exports Domestic 2023-24 2023-24 2023-24 2023-24 43% 46% 54% | e e e Formulations: APIs Formulations e e e e APIs Formulations ; Export Domestic : APIs @ Formulations @ APIs B® Domestic @ Exports B® Formulations @ APIs @ Formulations @ APIs
Slide 14: Revenue Break-up (Standalone)
Revenue Break-up (Standalone) 2023-24 2022-23 Crs | Domestic | Exports | Total | Domestic | Exports | Total Growth | © Branded Formulations 3,097.16 526.70 3,623.86 2,760.71 504.79 3,265.50 q pen isiton/ - 1,248.62 «1,248.62 : 1,134.40 1,134.40 © Total Formulations 3,097.16 1,775.32 4,872.48 2,760.7
Slide 15: Financials
Slide 16: Standalone
Standalone FY 2023-24 FY 2022-23 Zs US$ Mn | (Bers US$ Mn | % Growth @ Total Income 6,277.75 758 5,925.81 — e EBIDT 1,189.54 144 942.86 e EBIDT% 19.29% = 16.22% @ PBT* 955.52 115 750.49 e@ PBT% 15.5% = 12.91% @ PAT* 530.41 64 505.70 @ PAT% 8.60% = 8.70% # After forex gain of $21.84 Crs as against fo
Slide 17: Financials: Standalone Profitability
Financials Standalone CO Profitability | FY 2023-24 FY 2022-23 e PBIDT 19.29% @ point WB Pst WB PAT @ point WB Pst WB PAT
Slide 18: Business Characteristics
Business Characteristics Return on Capital Employed % (PBIT / Capital Employed) Return on Net Worth % (PAT / Net Worth) Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) Capital Employed Turnover Ratio (Total Income / Capital Employed) Asset Coverage Ratio (to term loan) (Net Fixed Assets
Slide 19: Financials: Standalone
Financials Standalone FY 2023-24 FY 2022-23 @ Net Profit 4.9% 41.2%
Slide 20: Standalone Q1 FY25
Standalone Q1 FY25 Q1 FY24 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 1,581.25 190 1,529.50 — e EBIDT 348.44 42 284.28 e EBIDT% 22.25% - 19.13% @ PBT* 287.89 35 249.78 e@ PBT% 18.4% - 16.81% @ PAT* 204.13 24 166.58 @ PAT% 13.03% - 11.21% # After forex gain of €4.80Crs as against €13.45 Cr
Slide 21: Standalone Q2 FY25
Standalone Q2 FY25 Q2 FY24 Zs US$ Mn Zs US$ Mn | % Growth @ Total Income 1,827.94 218 1,698.80 e EBIDT 414.48 49 346.77 20% e EBIDT% 22.89% = 20.86% @ PBT 339.21 40 284.42 e@ PBT% 18.73% = 17.11% @ PAT* 244.12 29 162.13 @ PAT% 13.48% = 9.75% # After forex loss of €12.37 Crs as against forex gain of
Slide 22: Standalone Q3 FY25
Standalone Q3 FY25 Q3 FY24 ZCrs US$ Mn | | ZCrs US$ Mn | % Growth @ Total Income 1,680.09 199 1,523.71 — e EBIDT 403.26 48 279.03 e EBIDT% 24.25% - 18.52% @ PBT* 355.52 42 199.70 e@ PBT% 21.38% - 13.25% @ PAT* 267.56 32 136.94 @ PAT% 16.09% - 9.09% # Afterforex gain of €7.83 Crs as against forex los
Slide 23: Standalone Nine Months FY25
Standalone 9 Mths FY25 9 Mths FY24 Zs US$ Mn | (Bers US$ Mn | % Growth @ Total Income 5,089.28 606 4,752.01 — e EBIDT 1,166.18 139 910.08 e EBIDT% 23.14% = 19.55% @ PBT 982.62 117 733.90 e@ PBT% 19.50% = 15.76% @ PAT* 715.81 85 465.65 @ PAT% 14.20% = 10.00% # Afterforex gain of €0.26 Crs as against
Slide 24: Consolidated FY 2023-24
FY 2023-24 FY 2022-23 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 7,829.81 945 6,369.94 e EBIDT 1,288.21 156 958.28 e EBIDT% 16.72% - 15.35% e@ PBT* 842.67 102 745.29 @ PBT% 10.94% - 11.94% e@ PAT* 547.35 66 471.32 @ PAT% 7.10% - 7.55% # After forex gain of €32.95 Crs as against forex loss o
Slide 25: Financials: Consolidated Business Characteristics
Financials Consolidated Business Characteristics FY 2023-24 FY 2022-23 Return on Capital Employed % (PBIT / Capital Employed) 16.30% 15.21% Return on Net Worth % (PAT / Net Worth) 11.47% 10.71% Fixed Asset Turnover Ratio (Total Income / Net Fixed Assets) 2.12 2.92 Capital Employed Turnover Ratio (To
Slide 26: Financials: Consolidated
Financials Consolidated FY 2023-24 FY 2022-23 @ Net Profit 9.2% 46.7%
Slide 27: Consolidated Q1 FY25
Q1FY25 Q1 FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 2,113.24 253 1,630.06 e EBIDT 387.49 46 294.33 e EBIDT% 18.52% - 18.57% e@ PBT* 290.39 35 251.82 @ PBT% 13.88% - 15.89% @ PAT* 192.24 2 162.82 @ PAT% 9.19% - 10.27% # After forex gain of €5.23 Crs as against €13.49 Crs for previous
Slide 28: Consolidated Q2 FY25
Q2 FY 25 Q2 FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 2,381.16 284 2,072.50 e EBIDT 449,83 54 358.77 e EBIDT% 19.10% - 17.64% e@ PBT* 344.83 35 225.36 @ PBT% 14.64% - 11.08% @ PAT* 229.48 27 145.06 @ PAT% 9.74% - 7.13% # After forex loss of $8.35 Crs as against forex gain of €1.79 Cr
Slide 29: Consolidated Q3 FY25
Q3 FY 25 Q3 FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 2,265.48 268 2,075.30 e EBIDT 446.07 53 330.52 e EBIDT% 19.87% - 16.10% e@ PBT* 367.92 44 220.43 @ PBT% 16.39% - 10.74% e@ PAT* 248.14 29 179.88 @ PAT% 11.05% - 8.76% # After forex gain of €17.01 Crs as against £0.36 Crs for previ
Slide 30: Consolidated Nine Months FY25
9 Mths FY 25 9 Mths FY 24 ZCrs US$ Mn | f ZCrs US$ Mn % Growth @ Total Income 6,759.88 805 5,777.86 e EBIDT 1,283.39 153 983.62 e EBIDT% 19.18% - 17.34% e@ PBT* 1,003.14 120 737.10 @ PBT% 14.99% - 13.00% @ PAT* 669.86 80 487.76 @ PAT% 10.01% - 8.60% # Afterforex gain of 13.89 Crs as against €15.64 (
Slide 31: Contribution of Therapeutic Groups
Financials Standalone Contribution of Therapeutic Groups a Therapeutic Segment — 2023-24 Domestic 2022-23 © Cardiovasculars& Anti-Diabetics © Anti-Malarials © Neuro Psychiatry e 3% 3% © Dermatology e 6% 6% © Neutraceuticals e % 1% Le es Export 2023-24 2022-23 © Cardiovasculars & Anti-Diabetics © Ant
Slide 32: Branded Formulations
Branded| Formulations
Slide 33: Branded Formulations: Domestic
Branded Formulations a Domestic . 22 Market leaders in All India Rank IQVIA Therapy Focused Over 4000 Rheumatoid Arthritis 16" (MAT Dec’24) Marketing Divisions Wholesalers & Anti-malarials Gy @ 24 Depots & Field Strength 6 brands among ‘1 C&F agent (PSR / BA)-6745 top 300 brands (Zerodol-SP, Zerodol
Slide 34: Branded Formulations Domestic Sales
Branded Formulations Domestic 3,097.16 ($374.Mn) 2,760.71 3000 2,508.27 ($344 Mn) ($337 Mn) 2500 1,981.67 2000 ($266 Mn) 1500 1000 500 —O- 2023-24 0 T T T 2020-21 L 2020-21 2021-22 2022-23 2023-24 ) pe Figures in Crores. Sales
Slide 35: Branded Formulations Future Growth Drivers
Branded Formulations Domestic Future Growth Clinical research as a tool to launch innovative combination Drivers formulations / NDDS. rail +e Strong brand building with focused promotion. +—® In-licensing / out-licensing to build business in the promoted therapy. Portfolio optimisation, strategies t
Slide 36: International
\ Intern ational
Slide 37: International Business
International Business a Registrations in 61 countries © Recognised _A Field-force to promote brands © Five Star Export gu in more than House 30 countries Products of the company 43% sales & Marketing offices in are now exported to over From exports By 12 countries 100 countries across the globe
Slide 38: International Business Sales
International Business (— > 3000 %2,717.19 2,643.42 %2,707.70 ($365 Nin) we (8330 Ma) ($327 Mn) 2500 2000 1500 1000 500 —O- 2023-24 0 T T T 1 2020-21 L 2020-21 2021-22 2022-23 2023-24 ) O- mun Figures in Crores. Sales 38
Slide 39: Continent-wise Exports 2023-24
International Business a Continent-wise Exports 2023-24 (%Crs) Continent Formulations APIs | Total | % Contribution © Europe 468.73 315.26 783.99 29% © Africa 477.76 42.69 520.45 19% © Americas 184.88 255.49 440.37 16% @ Asia 134.18 267.10 401.28 15% e dls 206.76 45.89 252.65 9% © Australasia 303.01
Slide 40: International Formulations
Slide 41: International Formulations Sales
International Formulations 21,597.19 ~ %1,639.19 21,775.32 ($214 Mn) 204 Mi 1,486.74 Cony ($200 Mn) —O- 2023-24 XX T T 1 2020-21 2021-22 2022-23 2023-24 2021-22 yw, 2022-23 Figures in Crores. Sales 41
Slide 42: International
Intern ational
Slide 43: International Branded Formulations Sales
International Branded Formulations (— 526.70 > 530 504.79 ($64 Mn) 510 ($63 Mn) 490 470 450 %415. 430 £403.42 cae ($54 Mn) 410 390 370 350 —O— 2023-24 330 T T T 1 2020-21 L 2020-21 2021-22 2022-23 2023-24 pa Figures in Crores. Sales 4B
Slide 44: International Branded Formulations Future Growth Drivers
International Branded Formulations Future Growth _ Thrust on brand building in Pain, CVS, CNS, Anti-infective Drivers and Anti-malarial segments. ral '—® Geographical expansion in covered countries through additional field force. '—® Expansion in business lines - Institutions and Distributors. Intro
Slide 45: International: Generics / Institution / Tender
@ eo ae tional NS nstitution / Tender so Ane SS 5
Slide 46: International Generics / Institution / Tender
International Generics / Institution / Tender >) Count Products Products Under 1400 e1403.77 Tues ountry Registered Registration 160M 1,134.40 ited Ki 1200 ($160 Mn) ome (141 Mn) United Kingdom 57 4 ($144 Mn) / Europe 1000 Australia / New Zealand @ é 800 South Africa 53 10 cou United States / 47 16
Slide 47: International Generics Future Growth Drivers
International Generics Future Growth Drivers Dossiers developed by company approved in UK are being taken for registration in other EU countries. al Formulations registered to be backed by own API. Sale of generic dossiers with or without supply agreements. Contract manufacturing arrangements. Futur
Slide 48: International: APIs
internat ational
Slide 49: International APIs Sales
International ~ APIs 1,120.00 1200 (6151 Mn) %1,021.39 %1,004.23 ($137 Mn) ($125 Mn) £932.38 1000 (5113 Mn) 800 600 400 200 —O- 2023-24 0 T T T 2020-21 L 2020-21 2021-22 2022-23 2023-24 pa Figures in Crores. Sales
Slide 50: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 1 1 Alendronate Sodium () cs - 7) - i} 2 2 Allopurinol (7) @ = = CEP @ 3 3 Amlodipine Besylate () - - - @ 4 Amlodipine Besylate (AK4 Process) - - - = ° G@ 4 5 Amodiaquine HCI = S @ - - - 5 6 A
Slide 51: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 11 12 12 13 13 14 14 15 15 16 16 7 18 17 19 18 20 21 19 22 Name of the API Benzarone Benzbromarone Bisoprolol Fumarate Bupropion Hydrochloride Carvedilol Celecoxib Cetrizine Hydrochloride (CZ Process) Cetrizine Hydrochloride (CZ5 / CZ6 Process) Chloroquine Phosphate Chlort
Slide 52: APIs - Drug Master Files
International APIs - Drug Master Files 31 Famotidine (FM3 Process) 2 - - i] - 27 32 Fenofibrate = 2 - - - 28 33 Fluconazole > 2 - - - AA DME | Name of the API US-FDA Canada- wHo | /Pa% | Australia| EQDM 20 23 Citalopram HBR - = = o - @ 21 24 __Dihydroartemesinin - = Gg - - - 22 25 Donepezil Hydrochl
Slide 53: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Dec’24 (Based on DMFs Sr. No.) API | DMF Canada- Japan- Sr. No.| Sr. No. Name of the API US-FDA HPEB WHO PMDA Australia EQDM | 0 35 Furosemide @ — : i) CEP @ 36 Furosemide (Veterinary) a re 38 Hydrochlorothiazide (Process |) 32. 39 ~—_-Hy
Slide 54: APIs - Drug Master Files
International APIs - Drug Master Files AA DME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 37 45 Lamotrigine - = = 2 - () 46 Losartan Potassium (LB3 Process) (7) 2 2 - - . 38 47 Losartan Potassium (LB4 Process) - - 2 2 - (7) 48 Losartan Potassium (LB7 Process) = g - - = i) 39 49 Lumef
Slide 55: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Dec’24 (Based on DMFs Sr. No.) API | DMF 7 Canada- Japan- si A F | Name ofthe AP | US-FDA | wre | WHO PMDA EQDM | 56 Methylphenidate HCI ee 58 Metoclopramide HCI 59 Metoclopramide HCl (M Process) ce 61 Metoprolol Tartrate 62 Metoprolol Ta
Slide 56: APIs - Drug Master Files
API | DMF Sr. No.| Sr. No. 53 67 54 68 55 69 56 70 57 71 58 72 59 73 60 74 61 75 62 76 63 77 Name of the API Ondansetron Base Ondansetron Hydrochloride Paroxetine HCI Piperaquine Phosphate Primaquine Phosphate Probenecid Proguanil Hydrochloride Propranolol HCI Pyrantel Embonate Pyrantel Pamoate Pyri
Slide 57: APIs - Drug Master Files
International ; APIs - Drug Master Files API-DMFs Filed as on Dec’24 (Based on DMFs Sr. No.) API | DMF 7 Canada- Japan- sth A al Name of the API | US-FDA | anadl | wHo | /apan- ae | sete EQDM | 78 Quetiapine Fumarate @ @ = CEP ; 79 Quetiapine Fumarate (QT5 Process) ec 81 Risendronate Sodium Hemi-Pen
Slide 58: APIs - Drug Master Files
International APIs - Drug Master Files oA. OME | Name of the API usFoa | Canada yg | JPan justralia | EQDM 72. 89 __Triamterene @ c c c c @ 90 Trimethoprim - - - Gg CEP (7) B 91 Trimethoprim (T Process) (7) - - - - - 92 Trimethoprim (14 Process) g - - - - - 74 93 Valsartan (VA6 Process) @ - - - - (7
Slide 59: International APIs Future Growth Drivers
International APIs -—® Consolidate API business of Sartans across the globe. Future Growth Drivers ‘—© Long term strategic tie-ups with major South American / European formulators. Leverage the customer base of more than 1000 customers spread across 90 _A countries is well laid down platform to intr
Slide 60: Research & Development
AS Resear rh& Development
Slide 61: Research & Development: R&D Spending
Research & Development APls & Formulations ( >) Year | TCs | sta saes | 180 156.49 161.50 4.50% \ 2.64% 160 u 46.46 271% 4.00% 2019-20 101.04 2.35% %126.67 140 545% 3.50% 2020-21 126.67 2.49% 120 Mis 200% 2021-22 141.46 2.63% 100 2.50% 80 2.00% 2022-23 156.49 271% 60 1.50% 2023-24 161.50 2.64% 40 1.
Slide 62: Research & Development: APIs & Formulations
Research & Development APls & Formulations -—® Current scientist manpower of 625+. Research focus on developing APIs with non-infringing process and development of finished dosage forms. Development of NDDS for domestic and international market. 248 patent applications filed. Biotech / fermentation
Slide 63: Overview of Advanced Biotech Lab
Overview of Advanced Biotech Lab Biosimilar R&D and Bio-manufacturing -—® Established “state-of-the-art” R&D in 2015 for Mammalian based mAbs Capable of in-house development from “Clone to Commercialization” Single-use CGMP Bio-manufacturing Facility (DS+DP+QC) is being established and to be ready b
Slide 64: Strong Biosimilar Pipelines
Strong Biosimilar Pipelines 7 Molecules: Anti-cancer , Anti-inflammatory and OpthalmicmAbs Stage of Development [ Molecules e 7 Monoclonal antibodies (mAbs) and One Non-mAb MAA/Launch Biosimilar at various stages of the development UK/HC/IN/EU © Target markets India, UK, HC, EU, ROW mt sas amor | —
Slide 65: Thank You
Ipca Laboratories — Investor Presentation (December 2024) on 6ix